Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. Disease progression results in stiffness and pain, especially in the hands and feet, which hinders the mobility of the patient and can have a substantial impact on quality of life. Therapeutic options for the treatment of RA have grown rapidly over the past two decades, having also expanded to encompass a number of highly successful biologics. Although clinically and commercially successful, there are a number of unmet needs in this market.
The differences between many of these products are relatively nuanced, and must be understood fully by companies seeking to position a novel drug in this market. This tabular heat map framework, designed to provide an easily digestible Summary of these clinical characteristics, provides detailed readouts of all late-stage clinical trial results for products in the RA market and Phase III pipeline. These are split along lines of therapy, and so are reflective of the treatment algorithm used in the clinic.
All safety and efficacy endpoints reported in these trials are displayed, for both the drug and placebo groups. In addition, key study characteristics such as the size, composition and patient segment of the study population, are provided. These results are presented in a visually accessible, color-coded manner in order to maximize ease-of-use.
The accompanying text provides a detailed analysis of the clinical benchmarks set by the current market landscape, and the anticipated changes to these benchmarks, and to the treatment algorithm, as a result of the late-stage pipeline.
The rheumatoid arthritis market landscape is expected to change substantially with the advent of promising novel pipeline products. - What are the clinical characteristics of currently approved therapies for rheumatoid arthritis, in terms of specific safety and efficacy parameters? - What are the key unmet needs in this indication, and which clinical safety and efficacy parameters are the most closely linked to them? - How will current late-stage IL-6 inhibitors affect the market for biologic DMARDs, and are they able to yield comparable clinical efficacy results to TNF-a therapies? - With four targeted synthetic DMARDs present in the late-stage pipeline, do they have sufficient differentiating characteristics to make a strong impact on the market? - How will the influx of biosimilar TNF-a inhibitors affect the competitive landscape?
Reasons to buy
- Understand the current clinical landscape by considering the treatment options available for each patient segment. - Visually compare the currently approved treatments available at each line of therapy, based on the most important efficacy and safety parameters tested in clinical trials. - Assess the current late-stage pipeline, in terms of the likely positioning of each product and the implications for the clinical landscape at each line of therapy - Understand the relative strengths and weaknesses of the studies used to gather these data. - Build up a nuanced understanding of the clinical benchmarks set by these products, and consider how the current late-stage pipeline will affect these benchmarks - Assess one’s own pipeline program in light of these benchmarks in order to optimally position this program and maximize uptake by clinicians
Our reports have been used by over 10K customers, including:
Aryl Hydrocarbon Receptor - Drugs In Development, 2021 Summary According to the recently published report ’Aryl Hydrocarbon Receptor - Drugs In Development, 2021’; Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) pipeline Target constitutes close to 29 molecules....
Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 126.96.36.199) - Drugs In Development, 2021 Summary Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 188.8.131.52) - Frataxin is a protein encoded by the FXN gene. It promotes the biosynthesis of heme and assembly and repair of iron-sulfur...
175 pages •
By The Business Research Company
• Jul 2021
Major players in the alpha mannosidosis market are Chiesi Farmaceutici S.p.A., Nuo Therapeutics, and Zymenex. The global alpha mannosidosis market is expected to grow from $7.50 million in 2020 to $8.89 million in 2021 at a compound annual growth rate (CAGR) of 18.6%. The growth is mainly due to increasing prevalence of alpha mannosidosis,...
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this U.S. In-vitro Fertilization Market Report
The U.S. in-vitro fertilization market by revenue is expected to grow at a CAGR of 5.45% during the period 2021–2026.
U.S. IN-VITRO FERTILIZATION INDUSTRY INSIGHTS
Over the past few years,...
RNA therapeutics is a rapidly expanding area of next-generation biological drugs.RNA is a versatile molecule and naturally regulates gene expression, either by upregulation or downregulation.
This function is employed to design novel RNA therapeutics. The fundamentals of RNA therapeutics consists of delivering functional RNA at a...
“Axial spondyloarthritis - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Axial spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route...
184 pages •
By Global Industry Analysts
• Apr 2021
- Global Algae Fats Market to Reach $1.2 Billion by 2027
- Amid the COVID-19 crisis, the global market for Algae Fats estimated at US$875.5 Million in the year 2020, is projected to reach a revised size of US$1.2 Billion by 2027, growing at aCAGR of 4.9% over the period 2020-2027. Foods & Supplements, one...
Arthritis (Musculoskeletal) - Drugs in Development, 2021 Summary Arthritis (Musculoskeletal) - Drugs in Development, 2021 provides an overview of the Arthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Arthritis, complete with...
Sarcopenia (Musculoskeletal) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Sarcopenia - Drugs in Development, 2021, provides an overview of the Sarcopenia (Musculoskeletal Disorders) pipeline landscape. Sarcopenia is an aging-associated...
In Patient Number
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.